List of Edurant drug patents
Edurant is owned by Janssen Prods.
Edurant contains Rilpivirine Hydrochloride.
Edurant has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Edurant are:
- US8101629
Edurant was authorised for market use on 20 May, 2011.
Edurant is available in tablet;oral dosage forms.
Edurant can be used as in combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naive adult patients, as set forth in the labeling, including i&u section; treatment in combination with cabotegravir of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure; in combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy.
The generics of Edurant are possible to be released after 21 April, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(2 months from now) | |
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(5 months ago) | |
| US7638522 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(2 months from now) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; In combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naive adult patients, as set forth in the labeling, including i&u section; Treatment in combination with cabotegravir of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure; In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic